| NOD2/CARD15 Variants Are Not a Risk Factor for Clinical Outcome after Nonmyeloablative Allogeneic Stem Cell Transplantation. | |
| | |
MedLine Citation:
|
PMID: 21215810 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Single nucleotide polymorphisms (SNPs) in the innate immunity receptor NOD2/CARD15 have been demonstrated to modulate the outcome of allogeneic hematopoietic stem cell transplantation (SCT). The effect of NOD2/CARD15 polymorphism is reported to be associated with type of donor (sibling or matched unrelated donor) as well as type of conditioning regimen. We reviewed NOD2/CARD15 SNPs in all donor/recipient pairs of 192 consecutive patients who received nonmyeloablative allogeneic SCT at our institution between 2002 and 2006. All patients were treated with fludarabine 30 mg/m(2)/day for 3 days followed by 200 cGy total-body irradiation (TBI) (n = 154) or TBI alone (n = 38) and received grafts from HLA-matched related (n = 132) or unrelated (n = 61) donors. NOD2/CARD15 polymorphisms were observed in 36 of 192 (19%) patients and in 35 of 192 (18%) donors. The incidences of acute and chronic graft-versus-host disease (aGVHD, cGVHD) were 39% and 49%, respectively, in patients with NOD2/CARD15 variants versus 51% and 61% in patients with wild type. The relapse rate at 3 years was 38% in patients with variants and 36% in patients with wild type. The incidence of transplant-related mortality was 22% for patients with variants and 21% for patients with wild type. Overall survival (OS) at 3 years was 56% in patients with variants and 64% in patients with wild-type NOD2/CARD15. There was no significant impact of NOD2/CARD15 mutations on clinical outcome (all P > .05, Kaplan Meier and Fine and Gray's tests). These data indicate that mutations in the NOD2/CARD15 gene are not a risk factor for clinical outcome in nonmyeloablative allogeneic SCT. Therefore, screening for NOD2/CARD15 polymorphisms in patients or donors does not have additional value in patients undergoing nonmyeloablative SCT. |
| | |
Authors:
|
Hanneke M van der Straaten; Martine M Paquay; Marcel G J Tilanus; Nan van Geloven; Leo F Verdonck; Cynthia Huisman |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-1-6 |
Journal Detail:
|
Title: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation Volume: - ISSN: 1523-6536 ISO Abbreviation: - Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-1-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9600628 Medline TA: Biol Blood Marrow Transplant Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Under...
Next Document: ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell...